Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Anatara Lifesciences Ltd ( (AU:ANR) ) has shared an update.
Anatara Lifesciences Ltd has completed Stage 2 of its GaRP-IBS Phase II trial, revealing positive trends in symptomatic relief for pain and abdominal distension, although the primary endpoint of statistical significance in IBS-SSS reduction was not achieved. The trial’s secondary endpoint showed significant improvement in anxiety scores, and the company is considering potential commercial discussions based on these outcomes.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is a developer of evidence-based, innovative products focusing on significant unmet needs in human health, particularly conditions involving the gastrointestinal tract (GIT).
Average Trading Volume: 2,597,358
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$1.28M
Find detailed analytics on ANR stock on TipRanks’ Stock Analysis page.